Osimertinib
CAS 1421373-65-0
In Stock
Osimertinib
Cat. No. ANT-OMT-00CAS 1421373-65-0In Stock
Technical Data
Cat. No.ANT-OMT-00
CAS1421373-65-0
Mol. FormulaC28H33N7O2
Mol. Weight499.61 g/mol
IUPACN-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide
SMILESCN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
InChIInChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)
InChI KeyDUYJMQONPNNFPI-UHFFFAOYSA-N
PurityNA
Description
Overview
Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.The most common side effects include diarrhea, rash, musculoskeletal pain, dry skin, skin inflammation around nails, sore mouth, fatigue and cough.Osimertinib was approved for medical use in the United States in November 2015,and in the European Union in February 2016
Anant Labs manufacture and furnish high quality Osimertinib impurities for global markets. Our Osimertinib EP Impurities are used by API manufacturers and fully integrated pharmaceutical companies worldwide.
Synonyms
N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamideosimertinib1421373-65-0AZD-9291AZD9291MereletinibAZD 9291osimertinibumN-(2-{[2-(Dimethylamino)ethyl](Methyl)amino}-4-Methoxy-5-{[4-(1-Methyl-1h-Indol-3-Yl)pyrimidin-2-Yl]amino}phenyl)prop-2-Enamide3C06JJ0Z2O
